Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 7,726 shares, a drop of 74.1% from the December 31st total of 29,780 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average trading volume of 32,128 shares, the short-interest ratio is currently 0.2 days. Based on an average trading volume of 32,128 shares, the short-interest ratio is currently 0.2 days. Currently, 1.1% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Quoin Pharmaceuticals stock. GAMMA Investing LLC increased its stake in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) by 649.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,084 shares of the company’s stock after acquiring an additional 1,806 shares during the quarter. GAMMA Investing LLC owned approximately 0.25% of Quoin Pharmaceuticals worth $30,000 at the end of the most recent reporting period. 8.63% of the stock is currently owned by hedge funds and other institutional investors.

Quoin Pharmaceuticals Stock Performance

NASDAQ QNRX traded down $1.08 during mid-day trading on Friday, reaching $7.22. 57,770 shares of the stock were exchanged, compared to its average volume of 36,118. Quoin Pharmaceuticals has a 1 year low of $5.01 and a 1 year high of $41.80. The business’s 50 day moving average is $13.45 and its 200-day moving average is $10.94. The company has a market capitalization of $6.06 million, a P/E ratio of -0.23 and a beta of 1.59.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its earnings results on Thursday, November 6th. The company reported ($6.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.36) by ($0.35). Equities analysts predict that Quoin Pharmaceuticals will post -2.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Wall Street Zen upgraded Quoin Pharmaceuticals to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.